Want to see PASG full AI Analyst Report?
Total Valuation
Passage Bio has a market cap or net worth of $15.04M. The enterprise value is -$10.48M.
Market Cap$15.04M
Enterprise Value-$10.48M
Share Statistics
Passage Bio has 3,212,810 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,212,810
Owned by Insiders21.93%
Owned by Institutions41.91%
Financial Efficiency
Passage Bio’s return on equity (ROE) is -2.43 and return on invested capital (ROIC) is -100.90%.
Return on Equity (ROE)-2.43
Return on Assets (ROA)-0.73
Return on Invested Capital (ROIC)-100.90%
Return on Capital Employed (ROCE)-1.10
Revenue Per Employee0.00
Profits Per Employee-758.70K
Employee Count60
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Passage Bio is ―. Passage Bio’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.00
Price to Fair Value2.00
Price to FCF-1.19
Price to Operating Cash Flow-0.49
PEG Ratio0.02
Income Statement
In the last 12 months, Passage Bio had revenue of 0.00 and earned -45.52M in profits. Earnings per share was -14.35.
Revenue0.00
Gross Profit-728.00K
Operating Income-43.15M
Pretax Income-45.52M
Net Income-45.52M
EBITDA-44.79M
Earnings Per Share (EPS)-14.35
Cash Flow
In the last 12 months, operating cash flow was -30.65M and capital expenditures 0.00, giving a free cash flow of -30.65M billion.
Operating Cash Flow-30.65M
Free Cash Flow-30.65M
Free Cash Flow per Share-9.54
Dividends & Yields
Passage Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.25
52-Week Price Change-45.96%
50-Day Moving Average5.29
200-Day Moving Average8.32
Relative Strength Index (RSI)41.15
Average Volume (3m)41.18K
Important Dates
Passage Bio upcoming earnings date is Jul 30, 2026, Before Open (Confirmed).
Last Earnings DateMay 19, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Passage Bio as a current ratio of 2.07, with Debt / Equity ratio of 48.97%
Current Ratio2.07
Quick Ratio2.07
Debt to Market Cap0.55
Net Debt to EBITDA0.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Passage Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Passage Bio EV to EBITDA ratio is -0.34, with an EV/FCF ratio of -0.48.
EV to Sales0.00
EV to EBITDA-0.34
EV to Free Cash Flow-0.48
EV to Operating Cash Flow-0.48
Balance Sheet
Passage Bio has $33.34M in cash and marketable securities with $5.75M in debt, giving a net cash position of $27.58M billion.
Cash & Marketable Securities$33.34M
Total Debt$5.75M
Net Cash$27.58M
Net Cash Per Share$8.58
Tangible Book Value Per Share$5.91
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Passage Bio is $11.75, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$11.75
Price Target Upside0.69% Upside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast42.29%